NYSE issues a pre-market daily advisory direct from the trading floor.

NEW YORK, Sept. 9, 2026 /PRNewswire/ — The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today’s NYSE Pre-market update for market insights before trading begins. 

Defense company Covenant has come out of stealth

Kristen Scholer delivers the pre-market update on September 9th

  • Moonwalk Bio says recent funding will advance RNAi development.
    • The startup says its treatments have demonstrated reductions in body weight and fat mass while preserving lean muscle mass.
    • Moonwalk’s lead development candidate is expected to enter first-in-human clinical studies in late 2027.
    • CEO Dr. Alex Aravanis will join NYSE Live to discuss the path forward for treatments.
  • Defense company Covenant opens a 105,000 square-foot factory in Texas.
    • The company introduced Anthem, a heavy-payload, long-range weapon system.
    • Covenant announced more than $250 million in funding across three rounds, with Andreesen Horowitz and Lightspeed among its backers.
  • ICE Brent Crude tops $100 a barrel amid the ongoing Middle East conflict.
    • This marks the first time the benchmark has reached triple digits since July.
    • The rise in oil prices comes ahead of a pair of inflation reading, which are set to come out later this week.

Opening Bell
Oracle (NYSE: ORCL) brings together customers for a unique experience

Closing Bell
LabCorp (NYSE: LH) celebrates 35 years as a listed company

For market insights, IPO activity, and today’s opening bell, download the NYSE TV App and check out the NYSE YouTube: TV.NYSE.com and YouTube.com/@NYSEofficial

XTEND AI Robotics at NYSE on September 8
XTEND AI Robotics at NYSE on September 8

Source link

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network
You May Also Like

Ascletis Announces Positive Topline Results from Its Phase III Open-Label Study of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne

–  Denifanstat (ASC40), a once-daily oral fatty acid synthase (FASN) inhibitor, demonstrated favorable…

Yonyou Launches "Cross-Border Transformation Forum" to Equip Businesses for Global Compliance and Digital Expansion

— Taipei and Vietnam Forums to Deliver Actionable Strategies for Tackling Localization,…

EurewaX Showcases at Money20/20 Asia, Secures Multiple Strategic Partnerships on Day One and Launches Payment Platform as a Service

BANGKOK, SINGAPORE and HONG KONG, April 21, 2026 /PRNewswire/ — On April…